Health Care Services Corporation Operates Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma and Texas
IRVINE, CA, and HERSTAL, BELGIUM - October 27, 2016 - MDxHealth SA (Euronext: MDXH.BR) today announced that Health Care Services Corporation (HCSC) has issued coverage for patients meeting the eligibility criteria established under the positive medical policy on the ConfirmMDx ® for Prostate Cancer test.
HCSC, a Mutual Legal Reserve Company and an Independent Licensee of the Blue Cross and Blue Shield Association, is the largest customer-owned health insurer in the United States and fourth largest overall, operating through HCSC's Blue Cross and Blue Shield® Plans in Illinois, Montana, New Mexico, Oklahoma and Texas. The company, founded in 1936, serves more than 15 million members across five states and employs more than 22,000 people in over 60 local offices.
MDxHealth continues to gain positive medical policies and coverage with PPO, commercial payors and other specialized networks; facilitating timely reimbursement for ConfirmMDx testing.
"This is the third Blue Cross Blue Shield (BCBS) Association licensee to establish a positive coverage policy and adds five more BCBS plans to the growing list of payers covering ConfirmMDx for Prostate Cancer," stated Dr. Jan Groen, CEO of MDxHealth . "We believe HCSC's decision is a significant step in providing national access to ConfirmMDx for Prostate Cancer, further expanding the impact on patient outcomes and reduction in cost to the US healthcare system. "
ConfirmMDx for Prostate Cancer is the first epigenetic, and only tissue-based test in the 2016 NCCN Guidelines for early detection of prostate cancer which addresses false negative biopsy concerns. It is the only molecular diagnostic test that provides a very high negative predictive value (NPV) of 96% for clinically significant prostate cancers, and 90% NPV for all prostate cancers, as well as prostate mapping of the test results to help guide repeat biopsies. Each year, more than 1 million American men undergo an invasive prostate biopsy with a negative result, however approximately 30% of those men actually have prostate cancer. The current standard of care for prostate biopsy procedures samples less than 1% of the prostate, leaving men at risk for undetected cancer and leading to a high rate of repeat biopsies, even on cancer-free men. ConfirmMDx for Prostate Cancer helps urologists identify low-risk men who may forego an unnecessary repeat biopsy and high-risk men who may benefit from intervention. To date more than 3,000 urologists have ordered ConfirmMDx on more than 45,000 patients. ConfirmMDx has qualified for Medicare reimbursement and covered by numerous private health insurance plans.
MDxHealth is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. The company's tests are based on proprietary gene methylation (epigenetic) and other molecular technologies and assist physicians with the diagnosis of cancer, prognosis of recurrence risk, and prediction of response to a specific therapy. For more information, visit mdxhealth.com and follow us on Twitter at: twitter.com/mdxhealth .
For more information:
Dr. Jan Groen, CEO
US: +1 949 812 6979
BE: +32 4 364 20 70
Jonathan Birt, Chris Welsh, Hendrik Thys (PR & IR)
Consilium Strategic Communications
UK: +44 20 3709 5701
US: + 1 917 322 2571 (Rx Communications Group LLC)
This press release contains forward-looking statements and estimates with respect to the anticipated future performance of MDxHealth and the market in which it operates. Such statements and estimates are based on assumptions and assessments of known and unknown risks, uncertainties and other factors, which were deemed reasonable but may not prove to be correct. Actual events are difficult to predict, may depend upon factors that are beyond the company's control, and may turn out to be materially different. MDxHealth expressly disclaims any obligation to update any such forward-looking statements in this release to reflect any change in its expectations with regard thereto or any change in events, conditions or circumstances on which any such statement is based unless required by law or regulation. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of MDxHealth in any jurisdiction. No securities of MDxHealth may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. securities laws.
NOTE: The MDxHealth logo, MDxHealth, ConfirmMDx, SelectMDx , AssureMDx and PredictMDx are trademarks or registered trademarks of MDxHealth SA. All other trademarks and service marks are the property of their respective owners.